Matteo Tamponi1, Domenico Gabriele2, Angelo Maggio3, Michele Stasi3, Giovanni B Meloni2, Maurizio Conti2,4, Pietro Gabriele5. 1. 1 ATS, Sardinia Regional Health Service , Sassari , Italy. 2. 2 Institute of Radiological Sciences University of Sassari , Italy. 3. 3 Medical Physics, Candiolo Cancer Institute - FPO , IRCCS, Candiolo (To) , Italy. 4. 4 Department of Diagnostic Imaging, AOU, University Hospital Trust of Sassari , Italy. 5. 5 Radiation Therapy, Candiolo Cancer Institute - FPO , IRCCS, Candiolo (To) , Italy.
Abstract
OBJECTIVE: This study was undertaken to model the biochemical free survival at 5 years and to evaluate the parameters defining dose-response curve, dose-fractionation radiosensitivity and repopulation. METHODS: It was carried out a literature search on Pubmed to retrieve data sets of patients treated with external beam radiation therapy of 1.8-4.0 Gy per fraction and overall treatment time of 3 to 10 weeks. 10 groups were identified, based on risk class and androgen deprivation therapy (ADT). Dose-response curve D50 (dose at 50% probability of control) and g50 (steepness), α/β (dose-fractionation radiosensitivity), and repopulation parameters, dprolif and Tprolif , were calculated. Bootstrap-based cross-validation was performed and median and 95% CI (confidence interval) were evaluated. RESULTS: 25 data sets, including 20,310 patients, were considered. The median (95% CI) D50 and g50 values were 62 (CI 53 - 66) Gy and 1.6 (0.8 - 2.4). ADT patients showed lower values of D50 and g50 (57 ± 5 Gy and 1.1 ± 0.4) compared to no-ADT patients (65 ± 2 Gy and 2.3 ± 0.6), with p < 0.0001 and p = 0.002. If we did not consider any dependence on overall treatment time, the median (95% CI) value of α/β was 1.4 (1.0 - 1.9) Gy with p < 0.0001 for all patients. The median values of dproli f and Tprolif were 0.0 to 0.3 Gy/d and 18-40 days. CONCLUSION: Dose-response curve resulted dependent on risk class and ADT, with higher steepness for no-ADT patients. Low values of dose-fractionation radiosensitivity were found, supporting the use of moderate hypofractionated radiotherapy in each risk class. A limited dependence on repopulation was observed. ADVANCES IN KNOWLEDGE: Prostate cancer response to moderate hypofractionated radiotherapy was reliably quantified considering risk class and androgen deprivation therapy.
OBJECTIVE: This study was undertaken to model the biochemical free survival at 5 years and to evaluate the parameters defining dose-response curve, dose-fractionation radiosensitivity and repopulation. METHODS: It was carried out a literature search on Pubmed to retrieve data sets of patients treated with external beam radiation therapy of 1.8-4.0 Gy per fraction and overall treatment time of 3 to 10 weeks. 10 groups were identified, based on risk class and androgen deprivation therapy (ADT). Dose-response curve D50 (dose at 50% probability of control) and g50 (steepness), α/β (dose-fractionation radiosensitivity), and repopulation parameters, dprolif and Tprolif , were calculated. Bootstrap-based cross-validation was performed and median and 95% CI (confidence interval) were evaluated. RESULTS: 25 data sets, including 20,310 patients, were considered. The median (95% CI) D50 and g50 values were 62 (CI 53 - 66) Gy and 1.6 (0.8 - 2.4). ADT patients showed lower values of D50 and g50 (57 ± 5 Gy and 1.1 ± 0.4) compared to no-ADT patients (65 ± 2 Gy and 2.3 ± 0.6), with p < 0.0001 and p = 0.002. If we did not consider any dependence on overall treatment time, the median (95% CI) value of α/β was 1.4 (1.0 - 1.9) Gy with p < 0.0001 for all patients. The median values of dproli f and Tprolif were 0.0 to 0.3 Gy/d and 18-40 days. CONCLUSION: Dose-response curve resulted dependent on risk class and ADT, with higher steepness for no-ADT patients. Low values of dose-fractionation radiosensitivity were found, supporting the use of moderate hypofractionated radiotherapy in each risk class. A limited dependence on repopulation was observed. ADVANCES IN KNOWLEDGE: Prostate cancer response to moderate hypofractionated radiotherapy was reliably quantified considering risk class and androgen deprivation therapy.
Authors: M J Zelefsky; D Cowen; Z Fuks; M Shike; C Burman; A Jackson; E S Venkatramen; S A Leibel Journal: Cancer Date: 1999-06-01 Impact factor: 6.860
Authors: A V D'Amico; D Schultz; M Loffredo; R Dugal; M Hurwitz; I Kaplan; C J Beard; A A Renshaw; P W Kantoff Journal: JAMA Date: 2000-09-13 Impact factor: 56.272
Authors: M W Skwarchuk; A Jackson; M J Zelefsky; E S Venkatraman; D M Cowen; S Levegrün; C M Burman; Z Fuks; S A Leibel; C C Ling Journal: Int J Radiat Oncol Biol Phys Date: 2000-04-01 Impact factor: 7.038
Authors: David J Brenner; Alvaro A Martinez; Gregory K Edmundson; Christina Mitchell; Howard D Thames; Elwood P Armour Journal: Int J Radiat Oncol Biol Phys Date: 2002-01-01 Impact factor: 7.038
Authors: Abigail N Pepin; Alan Zwart; Malika Danner; Marylin Ayoob; Thomas Yung; Brian T Collins; Deepak Kumar; Simeng Suy; Nima Aghdam; Sean P Collins Journal: Front Oncol Date: 2022-01-19 Impact factor: 6.244
Authors: Nuradh Joseph; Norman F Kirkby; Peter J Hoskin; Catharine M L West; Ananya Choudhury; Roger G Dale Journal: Br J Radiol Date: 2020-06-02 Impact factor: 3.039